NASDAQ$CMPS
COMPASS Pathways plc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
COMPASS Pathways reported financial results for the third quarter of 2022 and provided a business update.
COMPASS Pathways announced the finalization of its Phase 3 pivotal program design and progress in clinical trials, including the publication of Phase 2b trial data in The New England Journal of Medicine. The company's cash position at the end of the quarter was $173.1 million. The net loss for the quarter was $18.4 million, or $0.43 loss per share.
- Phase 3 pivotal program design finalized and on track to start in 2022; several clinical sites have been initiated
- Phase 2b trial data published in The New England Journal of Medicine
- Cash position at 30 September 2022 of $173.1 million
- Phase 3 program on track to commence in 2022
Headline financials
Revenue & EPS history
COMPASS · Revenue · Quarterly
$0
Forward guidance
The COMP360 Phase 3 pivotal program in treatment-resistant depression is designed to generate the evidence required for regulatory approval and to ensure commercial success through integration into healthcare systems. The company is on track to start the Phase 3 program this year and is making steady progress toward establishing the full global footprint for this program, which includes actively initiating new sites and training therapists.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q3 2022
-0.7%
Avg return
Earnings day
+0.6%
Avg return
5 days after
+4.1%
Avg return
30 days after
32%
6 / 19 earnings
Positive
+25.1%
Q2 2022
Best reaction
-23.3%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -5.9% | +12.7% | +29.1% | |
| Q3 2025 | -0.5% | +4.7% | -12.3% | |
| Q1 2025 | +0.5% | +4.3% | +28.3% | |
| Q4 2024 | +5.9% | +4.1% | -20.5% | |
| Q3 2024 | -23.3% | -27.0% | -25.8% | |
| Q1 2024 | +0.0% | -4.9% | -18.7% | |
| Q4 2023 | -7.2% | -12.1% | -32.7% | |
| Q3 2023 | +10.9% | +4.7% | +5.5% | |
| Q2 2023 | -4.7% | -8.8% | +4.2% | |
| Q1 2023 | -4.1% | -2.3% | -8.7% | |
| Q4 2022 | -3.4% | +0.8% | +23.3% | |
| Q3 2022 | +2.0% | -3.9% | +14.4% | |
| Q2 2022 | +25.1% | +18.1% | +4.6% | |
| Q1 2022 | -8.2% | +3.7% | +33.0% | |
| Q4 2021 | +8.1% | +15.5% | -1.1% | |
| Q2 2021 | -5.8% | -8.1% | +5.4% | |
| Q4 2020 | -1.2% | +4.5% | -5.9% | |
| Q4 2019 | -1.2% | +4.5% | -5.9% | |
| Q3 2020 | -0.2% | +1.4% | +61.6% | |
| Q1 2020 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro